Guest Feature - Managing Electronic submissions through eCTD with strategic partners

At the same time, pharmaceutical companies are finding this as a newer way to reduce time-to-market and minimize new product development cost.

By Editor on Oct 26, 2006

At the same time, pharmaceutical companies are finding this as a newer way to reduce time-to-market and minimize new product development cost.

This paper traces the business need and evolution of eCTD in pharmaceutical industry. It also highlights the importance of managing transition to eCTD and how companies need to align and adapt their submissions along with their extended partners.

To view the full PDF, please visit www.eyeforpharma.com/briefing/ectdfinal.pdf